Document Detail


Spironolactone therapy in hypertrichosis.
MedLine Citation:
PMID:  8980164     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although regarded as a benign condition, simple hypertrichosis may be very disturbing to a child cosmetically. An abnormality in androgen metabolism has been implied in the etiology of simple hypertrichosis recently. This study was undertaken to investigate the effect of spironolactone therapy for its antiandrogenic property in 12 prepubertal girls with hypertrichosis with no underlying etiology. The girls, with a mean age of 6.9 (1.2) years, had normal height and bone age. Basal hormone levels and adrenocorticotropin stimulation test results were in the normal ranges. Pelvic and adrenal ultrasound did not reveal pathology. Total and medullary hair width were measured from hair taken from preauricular, anterior midthigh, distal and proximal forearm areas. Spironolactone was started at an oral dose of 25 and increased to 100 mg x m(-2) x day(-1) twice daily for 1 year. Total hair width decreased significantly in the preauricular and anterior midthigh regions up to 6-9 months of treatment. Medullary hair width, which was affected by therapy to a greater extent, decreased significantly in all regions up to 6 months. Both total and medullary hair width showed a tendency to increase afterwards. No side effects were encountered. Spironolactone may be used in the treatment of simple hypertrichosis; however, more data are needed to clarify the efficacy and safety of anti-androgen therapy in hypertrichosis.
Authors:
F Darendeliler; F Bas; S Balaban; R Bundak; D Demirkol; N Saka; H Gunoz
Related Documents :
1531894 - Back school programs. the young patient.
17472204 - Exercise interventions as an adjunct therapy for psychosis: a critical review.
17681544 - Feedback of end-tidal pco2 as a therapeutic approach for panic disorder.
19675434 - Risk factor management: antiatherogenic therapies.
11583104 - Caffeine and exercise: metabolism, endurance and performance.
20176294 - Healthy brain aging: role of exercise and physical activity.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  135     ISSN:  0804-4643     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  1996 Nov 
Date Detail:
Created Date:  1997-02-04     Completed Date:  1997-02-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  604-8     Citation Subset:  IM    
Affiliation:
Istanbul Faculty of Medicine, Department of Pediatrics, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Androgen Antagonists / therapeutic use*
Child
Female
Hair / pathology
Humans
Hypertrichosis / drug therapy*,  pathology
Spironolactone / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased cardiovascular response to caffeine in perimenopausal women before and during estrogen the...
Next Document:  Water distribution in insulin-dependent diabetes mellitus in various states of metabolic control.